PCRX
Pacira BioSciences, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$36.43
+0.03%Price chart
Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29Nov 3Nov 6
Key dataNov 6, 2026
Open$36.42
From 52W high+0.00%
Volume534494.00
Market cap$1.46B
P/E (TTM)38.3x
P/S (TTM)2.0x
Div yield—
Key dataNov 6, 2026
Open
$36.42
From 52W high
+0.00%
Volume
534494.00
Market cap
$1.46B
ValuationView details →
P/E (Fwd)
11.3x
EV/EBITDA
11.9x
P/E (TTM)
38.3x
RSI (14)
83.3
MomentumView details →
1D Return
+0.03%
YTD Return
+40.79%
SummaryUpdated Sep 1, 2026
Pacira BioSciences, Inc. (NASDAQ:PCRX) is a Tampa, Florida-based specialty pharmaceutical company founded in 2006 that focuses on developing and commercializing non-opioid pain management and regenerative health solutions. Originally incorporated as Pacira Pharmaceuticals, the company rebranded to Pacira BioSciences in April 2019 to reflect its expanded focus beyond traditional pharmaceuticals into innovative biotechnology solutions. The company went public in February 2011 and has established itself as a leader in the non-opioid pain management space, addressing the critical need for alternatives to opioid-based treatments in surgical and chronic pain settings.
Similar companies
Latest newsMore news →
Kahn Swick & Foti, LLC said it is investigating the adequacy of the price and process in Pacira BioSciences’ proposed sale to Viatris, under which Pacira shareholders would receive $36.50 per share in cash.2d agoHalper Sadeh LLC said it is investigating whether Pacira BioSciences and its board violated their duties in connection with Pacira’s sale to Viatris for $36.50 per share in cash.7d agoBrodsky & Smith announced an investigation into potential claims against Pacira BioSciences' board concerning its proposed sale to Viatris.30d ago